• If you are wondering whether Biogen's current share price lines up with its underlying value, the recent performance gives you plenty to think about.
• The stock closed at US$189.13 recently, with returns of 3.1% over 7 days, 6.6% over 30 days, 6.4% year to date and 61.9% over the past year. The 3 year and 5 year returns sit at 39.8% and 32.1% declines respectively.
• These moves come as Biogen stays in focus in the large cap biotech space, with ongoing attention on its pipeline and portfolio position within the sector. Broader interest in pharmaceutical and biotech stocks has also kept Biogen on the radar of investors reassessing risk and potential opportunities.
• On Simply Wall St's valuation checks, Biogen currently scores 4 out of 6. This sets up a closer look at how different valuation methods stack up for this stock and points to an even more useful way to think about value that will be covered at the end of this article.

Approach 1: Biogen Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today to reflect time and risk. For Biogen, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections.

Biogen's last twelve month free cash flow is about $2.31b. Analyst estimates and subsequent extrapolations suggest free cash flow figures in the low to mid $2b range over the next decade, with a specific projection of $2.87b in 2030. Simply Wall St uses analyst inputs for the earlier years and then extends them using its own growth assumptions to build a full 10 year cash flow path.

Discounting these projected cash flows back to today and aggregating them results in an estimated intrinsic value of about $432.48 per share. Compared with the recent share price of US$189.13, the model output implies Biogen could be around 56.3% undervalued based on these assumptions and cash flow forecasts.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Biogen is undervalued by 56.3%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Biogen Price vs Earnings (P/E)

For profitable companies, the P/E ratio is a useful yardstick because it ties the share price directly to the earnings that support it. Investors usually expect higher P/E ratios when they see stronger earnings growth potential or lower perceived risk, and lower P/E ratios when growth looks more modest or risks appear higher.

Biogen currently trades on a P/E of 20.35x. This sits above the broader Biotechs industry average P/E of 17.62x, yet it is below the peer group average of 40.94x. That gap between industry and peer benchmarks can make it hard to know which comparison matters more for you as an investor.

Simply Wall St addresses this with its Fair Ratio, a proprietary estimate of what a more tailored P/E might look like for Biogen. The Fair Ratio of 21.73x reflects factors such as the company’s earnings growth profile, profit margins, industry, market cap and risk characteristics, rather than relying only on broad group averages. Because this figure is designed around Biogen’s own fundamentals, it can be more informative than a simple industry or peer comparison. With the current P/E of 20.35x sitting below the Fair Ratio, the multiple indicates that Biogen may be undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Biogen Narrative

Earlier sections highlighted that there is an even better way to think about valuation, and that is Narratives. In this approach, you set out your story for Biogen, link it to explicit assumptions for future revenue, earnings and margins, and then see how that story translates into a Fair Value that you can compare with the current share price to decide whether you see the stock as attractive, fully priced or expensive.

On Simply Wall St, Narratives sit inside the Community page and are designed to be simple to use. You can pick a view that fits your thinking or adjust the building blocks yourself, while the Fair Value updates automatically when fresh information such as earnings or news is incorporated into the underlying forecasts.

For Biogen, one investor might align with a more optimistic Narrative that assumes a Fair Value around US$273.20, while another might prefer a more cautious Narrative closer to US$150.59. By seeing both stories side by side and how each set of assumptions flows into a Fair Value number, you can decide which Narrative best matches your outlook before comparing it to the current price.

For Biogen however we will make it really easy for you with previews of two leading Biogen Narratives:

Both sit on the same underlying facts, but they apply different assumptions about how fast the business could grow, what margins might look like and what a reasonable P/E could be a few years from now. That is exactly where you get to decide which story feels closer to your own expectations before comparing it to the current share price.

Fair Value: US$273.20

Implied undervaluation vs recent close: about 30.8%

Revenue growth assumption: 5.79% a year

• Assumes stronger uptake of newer therapies such as LEQEMBI and SKYCLARYS, supported by better diagnostics, guidelines and an aging population that increases demand for neurology and rare disease treatments.
• Builds in higher profit margins over the next few years as operating leverage from new products and tighter cost control improves earnings, with earnings modeled to reach US$2.5b by around 2029.
• Uses a future P/E of about 20.1x on those earnings, which is above the current US Biotechs industry average used in the narrative, so this view effectively backs both higher earnings and a relatively full earnings multiple.

Fair Value: US$150.59

Implied overvaluation vs recent close: about 25.5%

Revenue growth assumption: 4.45% annual decline

• Emphasises pressure from pricing scrutiny, reimbursement hurdles and payer resistance, which could limit how much Biogen can charge for both existing and new therapies.
• Builds in tougher competition from generics, biosimilars and newer treatment approaches, along with the risk that key neurology trials or acquisitions do not translate into the earnings that some investors expect.
• Applies a lower future P/E of about 14.8x to 2029 earnings, below the US Biotechs industry figure cited in the narrative, on the view that the current market price already bakes in too much optimism around growth and profitability.

Together these Narratives bracket a wide fair value range and show how much your view on revenue trends, margins, and the right P/E multiple can shift the outcome. If you want to see the full set of bullish, bearish and community Narratives for Biogen in one place and track how they update over time, To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Biogen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Biogen? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.